ArticlesEffect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial
Introduction
The initial management of dyspepsia remains a challenge. The high prevalence of the condition substantially increases the workload for physicians and has detrimental effects on patient quality of life, as well as important socioeconomic consequences.1, 2 Unfortunately, solid evidence on which to base the best initial management strategy is still lacking.3, 4 Most studies to date have reported on single drug comparisons and mainly involved patients with persisting dyspeptic symptoms referred to secondary care. Several meta-analyses and reviews have been done to address important questions concerning treatment strategies for patients with dyspeptic symptoms.5, 6, 7, 8, 9 A Cochrane review showed that only a few studies—mostly of inadequate methodology—dealt with initial management of dyspepsia.5 The investigators concluded that large gaps in knowledge on the most cost-effective management strategy for uninvestigated dyspepsia exist. Consequently, guidelines for management of dyspepsia are inconsistent.
The American Gastroenterological Association (AGA) and Canadian guidelines recommend empirical proton pump inhibitor treatment for patients with predominant gastro-oesophageal reflux disease (GORD), and Helicobacter pylori test-and-treat followed by empirical proton pump inhibitor treatment for all others.10, 11 According to the AGA guidelines, empirical proton pump inhibitor treatment is also an initial option in a population with low H pylori prevalence. UK guidelines state that there is currently insufficient evidence to guide which of these two options should be offered first.12 Scottish guidelines adopt the ROME II definition for dyspepsia, necessitating initial endoscopy for diagnosis.13 They advise treating functional dyspepsia with antacids or H2-receptor antagonists, followed by H pylori test-and-treat when symptoms persist. By contrast, Dutch guidelines recommend empirical treatment with antacids or H2-receptor antagonists for all patients with new onset dyspepsia, and reserve proton pump inhibitor treatment for patients with persistent predominantly GORD symptoms, and H pylori test-and-treat for all other patients with persistient symptoms (step-up strategy).14 Direct endoscopic diagnosis is only indicated for patients presenting with alarm symptoms. Initial treatment with proton pump inhibitors is used widely because of its presumed superior cost-effectiveness.5 To improve our insight into the best treatment for initial management of dyspepsia in primary care, we undertook a double-blind, randomised controlled trial comparing step-up versus step-down therapy.
Section snippets
Patients
From October, 2003, to January, 2006 a representative sample of 312 Dutch family doctors (general practitioners)15 agreed to include patients in the DIAMOND study (Dutch study on Initial Management Of Newly diagnosed Dyspepsia). The methodological aspects of the trial are outlined here, and details have been described elsewhere.15
Patients aged 18 years and older who consulted their general practitioner for new onset dyspepsia were eligible. Dyspepsia was defined as pain or discomfort centred in
Results
150 (48%) of the participating general practitioners recruited 664 patients.15 The trial profile is shown in figure 2. 332 (97%) of 341 patients in the step-up, and 313 (97%) of 323 patients in the step-down group reached an endpoint with sufficient data for assessment. 19 patients (step-up n=9, step-down n=10) did not reach an endpoint (figure 2). Baseline characteristics are shown in table 1. During the study period, 139 (41%), 84 (25%), and 118 (35%) of 341 patients assigned to the step-up
Discussion
Ideally, dyspepsia treatment should quickly and conveniently alleviate patients' symptoms while also reducing the use of health-care resources to a minimum. We have shown that a step-up strategy starting with antacids is more cost effective than a step-down strategy starting with proton pump inhibitors in the initial management of dyspepsia in primary care. Compared with the step-down approach, the step-up regimen resulted in slightly lower medical and overall costs with equal clinical
References (40)
Management of dyspepsia: report of a working party
Lancet
(1988)Prevalence of upper gastrointestinal symptoms in the general population: a systematic review
Scand J Gastroenterol Suppl
(1999)Management of dyspepsia. Report No 2000/26
(2000)- et al.
Cost of endoscopy in economic evaluation
Gastroenterology
(1997) - et al.
Initial management strategies for dyspepsia
Cochrane Database Syst Rev
(2005) - et al.
Guidelines for the management of dyspepsia
Am J Gastroenterol
(2005) - et al.
Review article: uninvestigated dyspepsia and non-ulcer dyspepsia—the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy
Aliment Pharmacol Ther
(2004) - et al.
Cost-effectiveness of alternative approaches in the management of dyspepsia
Int J Technol Assess Health Care
(2003) American Gastroenterological Association medical position statement: evaluation of dyspepsia
Gastroenterology
(2005)
Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool
Can J Gastroenterol
Dyspepsia: management of dyspepsia in adults in primary care. Clinical guideline 17
Dyspepsia: a national clinical guideline. Report no 68
Multidisciplinary guideline “dyspepsia”
Pragmatic trials in primary care. Methodological challenges and solutions demonstrated by the DIAMOND-study
BMC Med Res Methodol
Definitions of dyspepsia
Scand J Gastroenterol Suppl
Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions
Am J Gastroenterol
Evaluation of a gastrointestinal symptoms questionnaire
Dig Dis Sci
EuroQol: the current state of play
Health Policy
Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff
Ned Tijdschr Geneeskd
Cited by (61)
Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial
2016, Journal of HepatologyCitation Excerpt :The PLD-Q is a recently developed and validated questionnaire for PLD patients that includes 13 items about frequency and discomfort of PLD-specific symptoms such as early satiety and abdominal pain [25]. The GI-Q includes 11 items related to abdominal symptoms [26,27]. Generic HRQL was measured by the medical outcomes study 36-item short-form health survey (SF-36) and the European organization for research and treatment of cancer quality of life questionnaire core-30 (EORTC).
Rising rates of proton pump inhibitor prescribing in US emergency departments
2014, American Journal of Emergency MedicineChaihu-Shugan-San, an oriental herbal preparation, for the treatment of chronic gastritis: A meta-analysis of randomized controlled trials
2013, Journal of EthnopharmacologyCitation Excerpt :However, despite all the standard chemotherapy, many patients continue to experience symptoms of nausea, epigastric burning pain, and bilious vomiting. Some patients cannot tolerate chemotherapy because of undesirable side effects and drug interactions (Cremonini et al., 2002; Kuipers et al., 2004; Stein et al., 1998; van Marrewijk et al., 2009). Therefore, a new agent that possibly works through other pathways could be helpful for patients unable to tolerate standard therapy.
Antacids revisited: review on contemporary facts and relevance for self-management
2022, Journal of International Medical Research